TP53 and melanoma: In addition, in the same pathology (NRAS-mutant melanoma cells with wild-type or mutant TP53), an MEK inhibitor (pimasertib) combined with a BCL2 inhibitor (ABT-199) or TP53 stimulator (PRIMA-1Met, APR-246) acted in a synergistic model toward apoptosis induction [98].